Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 12/20 | 0.71 |
| ▸ | LPL | P06858 | 11/20 | 0.71 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | F11 | P03951 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16768507 | 0.86 | LIPG (0.78) | LIPGLPLDGAT1F11 | |
| SCHEMBL22748422 | 0.85 | LIPG (0.97) | LIPGLPLTDP1L3MBTL1 | |
| SCHEMBL19026951 | 0.82 | LIPG (0.56) | LIPGLPL | |
| SCHEMBL14750160 | 0.81 | LIPG (0.91) | LIPGLPLF11 | |
| SCHEMBL31150275 | 0.81 | LPL (0.48) | LIPGLPL | |
| SCHEMBL16936864 | 0.80 | LIPG (0.74) | LIPGLPLF11CYP4F2CYP4A11 | |
| SCHEMBL17927354 | 0.80 | LIPG (0.74) | LIPGLPLDGAT1F11 | |
| SCHEMBL1744642 | 0.80 | LIPG (0.60) | LIPGLPLDGAT1F11 | |
| SCHEMBL2670630 | 0.78 | LIPG (0.53) | LIPGLPLF11HDAC1HDAC6 | |
| SCHEMBL22379978 | 0.78 | LIPG (0.67) | LIPGLPLDGAT1F11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846927-B2 | Inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2014-09-30 | — | — | US | disclosed |
| US-20130165477-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2013-06-27 | — | — | US | disclosed |
| US-8389541-B2 | Inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2013-03-05 | — | — | US | disclosed |
| US-20120108628-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | Mirati Therapeutics, Inc. | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165477-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | HGF, ERBB2, MET | LIPG 933/4885LPL 3131/4885DGAT1 4197/4885 |
| US-20120108628-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | HGF, ERBB2, MET | LIPG 933/4885LPL 3131/4885DGAT1 4197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.